'Teicoplanin' 10 times more effective in treating Covid-19 than HCQ: IIT Delhi research


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ 'Teicoplanin' 10 times more effective in treating Covid-19 than HCQ: IIT Delhi research
Teicoplanin is already approved by FDA

Clinically approved drug "Teicoplanin" is a potential therapeutic option against Covid-19 and can be ten times more effective than several drugs being currently used, research by Indian Institute of Technology (IIT), Delhi has found.

The research by the institute's Kusuma School of Biological Science screened an assemblage of 23 approved drugs, which have shown leads towards being therapeutic options for coronavirus.

"While the effect of Teicoplanin was compared with other important drugs in use, Teicoplanin was found to be 10-20 fold more effective than the chief drugs being used against SARS-CoV-2, such as Lopinavir and Hydroxychloroquine in our laboratory conditions," said Ashok Patel, Professor at IIT Delhi.

Patel, who led the research was also assisted by Dr Pradeep Sharma from AIIMS. The research has also been published in the International Journal of Biological Macromolecules.

Teicoplanin is an FDA-approved glycopeptide antibiotic, which is regularly used for treating Gram-positive bacterial infections with low toxicity profile in humans.

"Recently, there has been a clinical study carried out with Teicoplanin at Sapienza University in Rome. However, a more detailed clinical investigation is required on a large cohort, in different stages mild, moderate and critically ill patients to conclude the definite role of Teicoplanin against Covid-19," Patel said.

Globally, over 3.3 crore people have been infected with Covid-19, and the total number of deaths from the deadly virus now stands at over 10 lakh.

Story Courtesy

https://www.indiatoday.in/science/story/fda-approved-teicoplanin-10-times-more-effective-in-treating-covid-19-than-hcq-iit-delhi-research-1727075-2020-09-30 

Tags : #IItDelhi #Teicoplanin #Covid19Treatment #HCQ #FDA #ICMR #KusumaSchoolofBiologicalSciences #GlycopeptideAntibiotic

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026